# Immunooncology and Targeted Therapy Combinations for Advanced Renal Cell Carcinoma: Pharmacist Focus on Managing the Patient

# (Recorded Podcast)

### **Key References**

Brahmer JR, Abu-Sbeih H, Asceierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. *J Immunother Cancer*. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435

Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*. 2021;384(9):829-841. doi:10.1056/NEJMoa2026982

Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. *N Engl J Med*. 2021;384(14):1289-1300. doi:10.1056/NEJMoa2035716

NCCN Clinical Practice Guidelines in Oncology Kidney Cancer. Version 1.2023. National Comprehensive Cancer Network. June 17, 2022. Accessed July 1, 2022.

https://www.nccn.org/professionals/physician\_gls/pdf/kidney.pdf

Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*. 2019;380(12):1116-1127. doi:10.1056/NEJMoa1816714.

Rini BI, Battle D, Figlin RA, et al. The Society for Immunotherapy of Cancer consensus statement of immunotherapy for the treatment of advanced renal cell cancer (RCC). *J Immunother Cancer*. 2019;7(1):354. doi:10.1186/s40425-019-0813-8

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. *J Clin Oncol*. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440

#### **Patient Resources**

#### **Sources of information about RCC and its treatment:**

- 1. Kidney Cancer Association: <a href="https://www.kidneycancer.org/">https://www.kidneycancer.org/</a>
- 2. National Cancer Institute: <a href="https://www.cancer.gov/types/kidney">https://www.cancer.gov/types/kidney</a>
- 3. National Kidney Foundation: <a href="https://www.kidney.org/atoz/content/what-kidney-cancer">https://www.kidney.org/atoz/content/what-kidney-cancer</a>

#### Sources of information about treatment:

- 1. Immune Checkpoint Inhibitors: <a href="https://www.hoparx.org/patient-education/immunooncology-time-to-talk#linkICl">https://www.hoparx.org/patient-education/immunooncology-time-to-talk#linkICl</a>
- 2. Targeted Therapy: <a href="https://www.cancer.org/cancer/kidney-cancer/treating/targeted-therapy.html">https://www.cancer.org/cancer/kidney-cancer/treating/targeted-therapy.html</a>

## **Cancer support organizations:**

- 1. Kidney Cancer Association: https://www.inspire.com/groups/kidney-cancer-association
- 2. Kidney Cancer Cure: <a href="https://kccure.org/kidney-cancer-patient-support-communities/">https://kccure.org/kidney-cancer-patient-support-communities/</a>
- 3. Smart Patients: <a href="https://www.smartpatients.com/communities/kidney-cancer">https://www.smartpatients.com/communities/kidney-cancer</a>
- 4. Cancer Care: https://www.cancercare.org/diagnosis/kidney\_cancer